CellDx Tissue CellDx Tissue

Personalized Cancer Monitoring with Molecular-Level Accuracy

Detect What Scans Might Miss

Order Now

Overview

Target-MRD™ is an advanced blood-based test designed to detect Minimal Residual Disease (MRD)—microscopic cancer signals that remain in the body after treatment and are often undetectable by conventional imaging. Using highly sensitive circulating tumor DNA (ctDNA) analysis, Target-MRD™ identifies early molecular signs of recurrence, enabling clinicians to act months before clinical relapse becomes visible. By combining personalized (tumor-informed) and broad (tumor-agnostic) approaches, it delivers a more comprehensive and reliable assessment of residual disease.

Designed for Smarter Post-Treatment Monitoring

Transforming Follow-Up Care with Molecular Precision

Early Detection

Identify cancer recurrence at a molecular level before it appears on scans or symptoms

Personalized Monitoring

Track disease status based on individual tumor biology

Informed Decisions

Guide therapy adjustments with real-time molecular insights

Continuous Surveillance

Enable proactive follow-up with regular, non-invasive testing

The Next Generation of MRD Detection

Combining Precision, Sensitivity, and Breadth

Dual Approach Advantage

Integrates both tumor-informed and tumor-agnostic strategies for comprehensive detection

High Sensitivity

Detects extremely low levels of disease (LOD up to 0.01%)

Advanced Technology

Powered by NGS and ddPCR for accurate and reliable results

False Signal Reduction

CHIP correction ensures high specificity and confidence in results

Clinical Intelligence for Every Stage of Follow-Up

Actionable Insights Beyond Imaging

Recurrence Detection

Identify relapse earlier than conventional methods

Therapy Guidance

Support decisions to escalate, de-escalate, or continue treatment

Risk Assessment

Stratify patients based on relapse risk

Treatment Monitoring

Evaluate effectiveness of ongoing therapies

Dual-Layered MRD Profiling

Enabling High-Sensitivity Detection with Complementary Approaches

Tumor-Informed (TI)

Personalized, high-sensitivity tracking

Scope

  • Patient-specific somatic variants (from tumor tissue)
  • SNVs, Indels, CNVs (custom-selected)
  • Absolute quantification via ddPCR

Analytical Features

  • Ultra-sensitive detection (LOD: up to 0.01% VAF)
  • High specificity (low false positives)
  • Longitudinal tracking of known variants

Strength

  • Precise monitoring of residual disease burden
  • Ideal for minimal residual disease detection post-treatment
  • Reduced false positives through effective differentiation of tumor-derived vs CHIP variants

Tumor-Agnostic (TA)

Broad, adaptive mutation surveillance

Scope

  • SNVs, Indels, CNVs, fusions: Broader detection
  • No prior tumor data required
  • High-depth targeted NGS (~17,000×)

Analytical Features

  • Detection of emergent and resistance mutations
  • Captures tumor heterogeneity and evolution
  • LOD: ~0.1% VAF

Strength

  • Identifies new, treatment-induced, and subclonal variants
  • Enables dynamic disease monitoring beyond baseline profile
  • Ensures biologically relevant interpretation by excluding hematopoietic-origin (CHIP) variants
Clinical Utility Clinical Utility

Why Dual-Layer MRD Detection Matters

While single-method MRD approaches may miss either low-frequency residual disease or emerging variants, integrating tumor-informed and tumor-agnostic profiling improves detection, enabling a more comprehensive assessment of disease status. This approach ensures higher sensitivity and broader variant coverage, reducing the risk of missed molecular signals.

Clinical Applications Across the Treatment Journey

Designed for Real-World Oncology Challenges

TISSUE COLLECTION

  • FFPE tumor block
  • Adequate tumor content
  • Basis for patient-specific variant selection

BLOOD COLLECTION

  • ~30 mL peripheral blood
  • Strict tubes for cfDNA preservation

ANALYSIS

  • Tumor tissue sequencing
  • Paired tumor-normal analysis
  • Tumor-informed profiling

REPORTING

  • Integrated MRD status
  • Dual-layer report
  • Clinically actionable report

BASELINE MRD

Requires both tissue and blood samples to design the assay and establish baseline ctDNA status.

Tissue Collection
+
Blood Collection
→
Analysis (TI + TA)
→
Baseline MRD Result

FOLLOW MRD

Blood sample only for longitudinal monitoring using established markers and NGS surveillance.

Blood Collection Only
+
Analysis (TI + TA)
→
Follow-up MRD Result
Download Brochure

Frequently Asked Questions

What is ctDNA and why is it important? ›
Circulating tumor DNA (ctDNA) is small fragments of DNA released by cancer cells into the bloodstream. Detecting ctDNA allows for non-invasive monitoring of cancer and early detection of residual disease.
What is minimal residual disease (MRD)? ›
Minimal residual disease refers to a very small number of cancer cells that remain in the body after treatment. These cells are often undetectable through conventional imaging but may lead to cancer recurrence if not identified early.
What makes Target-MRD different from other MRD tests? ›
  • Combines tumor-informed and tumor-agnostic approaches
  • Detects both known and emerging mutations
  • Captures tumor heterogeneity and clonal evolution
  • Offers a high sensitivity with a limit of detection (LOD) of 0.01%
  • CHIP filtering to reduce false positives
Why is combining both approaches important?
Using both approaches ensures:
  • Detection of known mutations (high specificity)
  • Identification of new or evolving mutations (broad coverage)
  • Better monitoring of tumor evolution and resistance
When should MRD testing be performed?
MRD testing can be performed before treatment initiation to establish a baseline, after completion of treatment, during follow-up monitoring, and at regular intervals (e.g., every 6 months) to track disease status. Your oncologist will determine the optimal timing based on your condition.
Why do I need this test if my scan is clear? ›
Even when scans show no cancer, a few cancer cells may still remain. This test can detect those hidden cells early, helping doctors act before the cancer grows again. Target-MRD™ complements imaging and clinical evaluation. It provides molecular-level insights that imaging alone cannot detect.
How often will I need to repeat the test? ›
This depends on your cancer type and risk. Many patients take it every few months during follow-up, but your doctor will guide you.
How accurate is Target-MRD? ›
Target-MRD™ offers high sensitivity, with the ability to detect very low levels of disease (down to 0.01% variant allele frequency), making it highly effective for early detection of recurrence.
Is Target-MRD™ suitable for long-term monitoring?
Yes. It is specifically designed for longitudinal monitoring, enabling continuous tracking of disease status over time.
What do the results mean?
  • MRD Positive: Presence of ctDNA suggestive of higher risk of relapse of disease
How can I get Target-MRD testing done?

Not Sure Where to Start? Just Reach Out.

Every cancer journey is unique. Our team can help guide your next step.

Got An Enquiry?

Contact Us.